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Abstract
Important pain transducers of noxious stimuli are small- and medium-diameter sensory neurons that express
transient receptor vanilloid-1 (TRPV1) channels and/or adenosine triphosphate (ATP)-gated P2X3 receptors whose
activity is upregulated by endogenous neuropeptides in acute and chronic pain models. Little is known about the role
of endogenous modulators in restraining the expression and function of TRPV1 and P2X3 receptors. In dorsal root
ganglia, evidence supports the involvement of the natriuretic peptide system in the modulation of nociceptive
transmission especially via the B-type natriuretic peptide (BNP) that activates the natriuretic peptide receptor-A
(NPR-A) to downregulate sensory neuron excitability. Since the role of BNP in trigeminal ganglia (TG) is unclear, we
investigated the expression of BNP in mouse TG in situ or in primary cultures and its effect on P2X3 and TRPV1
receptors of patch-clamped cultured neurons. Against scant expression of BNP, almost all neurons expressed NPR-
A at membrane level. While BNP rapidly increased cGMP production and Akt kinase phosphorylation, there was no
early change in passive neuronal properties or responses to capsaicin, α,β-meATP or GABA. Nonetheless, 24 h
application of BNP depressed TRPV1 mediated currents (an effect blocked by the NPR-A antagonist anantin) without
changing responses to α,β-meATP or GABA. Anantin alone decreased basal cGMP production and enhanced control
α,β-meATP-evoked responses, implying constitutive regulation of P2X3 receptors by ambient BNP. These data
suggest a slow modulatory action by BNP on TRPV1 and P2X3 receptors outlining the role of this peptide as a
negative regulator of trigeminal sensory neuron excitability to nociceptive stimuli.
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Introduction
Sensory inputs, including painful and tissue-damaging
stimuli, are conveyed from the periphery to the central nervous
system through primary afferent neurons located in the
trigeminal ganglia (TG) and dorsal root ganglia (DRG). Small-
and medium-diameter sensory neurons (nociceptors) express,
amongst a range of membrane proteins detecting noxious
stimuli, capsaicin (and heat)-sensitive transient receptor
potential vanilloid-1 (TRPV1) channels and/or adenosine
triphosphate (ATP)-gated P2X3 subunit-containing receptors
[1,2] to transduce pain. In particular, several studies have
demonstrated TRPV1 to be essential for the development of
inflammatory thermal pain conditions [3–5]. Among ATP-gated
P2X receptors, the P2X3 receptors are almost exclusively
expressed by sensory ganglion neurons [6,7] and have been
implicated in craniofacial pain [8,9], including migraine [10].
The activity of TRPV1 and P2X3 receptors is known to be
upregulated by endogenous peptides, like bradykinin, CGRP or
substance P [11–15], and trophic factors like NGF and BDNF
[16–18]. Thus, the functional action of such modulators is
manifested as sensitization of these receptors, thereby
contributing to lowering pain threshold and to triggering pain,
especially of chronic nature. In this sense, their role on
trigeminal sensory neurons as facilitators of migraine pain has
been proposed [14,19–21]. As recently reviewed [22,23],
clinical studies have confirmed that P2X3 and TRPV1
receptors mediate pain induced by distinct stimuli in man.
Less is known about the potential role of endogenous
modulators in restraining the expression and function of TRPV1
and P2X3 receptors. Recent evidence supports a potential
involvement of the natriuretic peptide system in the modulation
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of sensory neuron nociceptive transmission [24–27]. Natriuretic
peptides (NPs) are a family of structurally related paracrine
factors, namely atrial NP (ANP), B-type NP (BNP), also known
as brain natriuretic peptide, and C-type NP (CNP) [28]. ANP
administration does not affect sensitivity to radiant heat [29] or
mechanical allodynia [26,27], while CNP is proposed as a
positive modulator of chronic pain [24]. Conversely, microarray
gene profiling has indicated that chronic pain enhances BNP
and its natriuretic peptide receptor-A (NPR-A) in rat DRG.
Moreover, BNP application reduces the excitability of DRG
nociceptors and the hyperalgesic response in a rat model of
inflammatory pain. This led to the suggestion that BNP may
play an inhibitory role in chronic pain [25]. BNP acts through
binding to NPR-A, which is a guanylyl cyclase receptor (also
sensitive to ANP), and increases intracellular cGMP levels
[30,31].
While all NPRs have been identified in brainstem trigeminal
nuclei [32–34], little is known about the possible role of the
natriuretic peptide system at TG level where nociceptive
signals are transduced [35–37]. A recent clinical report has
shown that BNP levels are raised in the jugular vein blood
during a migraine attack [38]. We have developed an in vitro
model system using primary cultures of mouse TG to
investigate the cellular mechanisms regulating the expression
and function of P2X3 and TRPV1 receptors [18,39]. Hence, the
present study was initiated to characterize BNP and NPR-A
expression in the mouse TG and to examine whether the BNP/
NPR-A system may modulate TRPV1 and P2X3 nociceptor
activity.
Results
BNP and NPR-A are expressed in vivo in adult mouse
TG
Gene expression of BNP and its receptor NPR-A
investigated by RT-PCR indicated weakly positive BNP and
strongly positive NPR-A bands of the expected size (199 bp
and 200 bp respectively; Figure 1 A). We next examined with
Western blot analysis if NPR-A protein was synthesized. The
NPR-A antibody recognized a single band of the expected size
(approximately 140 kDa) in mouse TG homogenates,
corresponding to the NPR-A protein. Conversely, BNP
expression was below detection. Thus, BNP expression was
evaluated by ELISA assay. Mouse BNP concentrations in
tissue extracts from entire TG and in the serum were 1.12 ±
0.34 pg/mg protein and 185.2 ± 47 pg/ml, respectively (n=6
mice). Western blot analysis confirmed that NPR-A receptor
was synthesized both in adult (P30) and in younger (P12)
animal TG (Figure 1 B). Thus, the properties of this peptide
could be investigated with younger tissues as well, a
convenient preparation for primary culture studies.
The distribution of NPR-A and BNP in mouse TG was further
examined by immunohistochemistry. We found that NPR-A
was expressed in most neurons, as shown by co-localization
with β-tubulin III (Figure 1 C). NPR-A immunoreactivity could
not be detected in other cell types. Further observations
(Figure S1 A) confirmed that the NPR-A staining appeared
colocalized with TRPV1 and P2X3 immunopositive neurons.
Unlike the data concerning its receptor, BNP immunopositive
cells were few and scattered elements, in which the peptide
staining appeared as small perinuclear granules (0.9 ± 0.4% of
total ganglion cells, n=3) (Figure 1 D). The few BNP-
immunoreactive cells seldom showed neuron-like morphology.
Characterization of BNP and NPR-A in TG primary
cultures
In order to examine the characteristics of BNP effects on TG
cells, we used TG primary cultures as previously reported
[18,39]. Consistent with our results from tissue sections, double
immunostaining for NPR-A and the neuronal marker β-tubulin
III showed that in vitro the receptor was expressed exclusively
by neurons (Figure 2 A). Figure 2 B summarizes the
distribution of NPR-A immunoreactivity in relation to the
neuronal cell body size which was the highest in neurons with
somatic diameter between 12 and 25 µm, consistent with the
higher prevalence of small and medium sized neurons in TG
[18]. Systematic cell counting indicated that the vast majority of
β-tubulin III-positive cells expressed NPR-A (91.3 ± 1.1%,
n=10), confirming the extensive colocalization of the two
proteins already observed in vivo. Western blot analysis with
biotinylation method validated the expression and membrane
localization of NPR-A (Figure 2 C).
Immunocytochemistry revealed the scant presence of BNP-
positive cells also in TG primary cultures, as they accounted for
only 2.0 ± 0.2% of the total cell population in our cultures
(n=12). The morphology of these cells appeared prevalently
non-neuronal (Figure 2 D, left), although rare neuron-like cells
were observed as well (Figure 2 D, right). We also estimated
(with ELISA assay) the concentration of BNP in primary
cultures and in their medium that was found to be 1.1±0.4
pg/mg and 4.9±2.6 ng/ml, respectively (n=8 mice).
Functional assays of NPR-A
We sought to understand whether the large expression of
membrane bound NPR-A was actually indicative of a functional
receptor system. To this end, since activation of NPR-A by
ANP and BNP has been shown to increase intracellular cGMP
production [40], we investigated if application of BNP to mouse
TG cultures could increase intracellular cGMP production, as
determined by ELISA. Figure 3 A shows that application of 100
or 500 ng/ml BNP (compared to the vehicle control treatment)
increase the mean cGMP levels in a concentration- and time-
related fashion. In fact, the cGMP rise was already detectable
after 5 min and reached its peak after 30 min with a late (1 h)
decline. The greatest increment was observed after 30 min
application of 500 ng/ml BNP. Even 100 ng/ml BNP was
sufficient to activate the NPR-A mediated pathways by
significantly increasing cGMP by almost 2-fold compared to
basal levels. This effect was prevented by the application of
500 nM anantin, a specific antagonist of NPR-A [41,42], that
completely inhibited the elevation of cGMP levels. A lower
anantin concentration (100 nM) failed to produce significant
antagonism of BNP-elicited rise in cGMP (Figure 3 A). It is
noteworthy that anantin (500 nM) per se significantly
decreased the basal level of cGMP.
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One important intracellular effect of NPR-A activation is
phosphorylation of Akt that occurs downstream of cGMP
synthesis [43]. We tested whether this phenomenon could be
also observed in TG cultures. Figure 3 B shows that after 10 or
30 min application of 500 ng/ml BNP, there was a significant
increase in Akt phosphorylation, an effect fully blocked by 500
Figure 1.  Expression of BNP and NPR-A in adult mouse TG in vivo.  A, PCR products (amplified with 40 cycles) identified by
ethidium bromide staining show RT-PCR amplification of BNP and NPR-A mRNA (+RT), as well as of the housekeeping gene
GAPDH. Negative control reactions for retrotranscription (-RT) do not show any bands. B, Chemiluminescence image of Western
blot showing protein expression of NPR-A in TG from P30 and P12 mice. β-Tubulin III was used as a loading control. C, Example of
confocal microscopy images showing the widespread colocalization of immunostaining for NPR-A (red) and β-tubulin III (green). Cell
nuclei are visualized with DAPI staining (blue). Scale bar, 100 µm. D, Representative confocal images of longitudinal sections of
adult TG. Immunohistochemistry reveals BNP-immunoreactive granules around few nuclei (DAPI). Among these cells, most
possess non-neuronal morphology (left panel); neuron-like cells are rarely immunostained (right panel). Scale bar, 30 µm.
doi: 10.1371/journal.pone.0081138.g001
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Figure 2.  BNP and NPR-A are expressed in mouse TG cultures.  A, Immunocytochemical analysis of NPR-A (red) and β-tubulin
(green) in mouse TG culture. Nuclei are visualized with DAPI (blue). Merge image (right) indicates extensive co-staining. Scale bar,
30 µm. B, Somatic size distribution of NPR-A-positive TG neurons. Data represent 119 NPR-A-positive neurons from 4 independent
experiments. C, Example of Western immunoblotting (representative of three experiments) showing the surface (obtained after
membrane biotinylation) and total expression of NPR-A in TG culture. β-Actin was used as loadingcontrol of the total extract. TfR is
the marker for correct biotinylation. D, Immunostaining for BNP (green) is mostly restricted to few cells with non-neuronal
morphology that display perinuclear immunoreactive granules (left panel). More rarely, some neuron-like cells are also stained for
BNP with granules extending along their processes (right panel). Nuclei are visualized with DAPI staining (blue). Scale bar, 30 µm.
doi: 10.1371/journal.pone.0081138.g002
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Figure 3.  cGMP production by mouse TG cultures.  A, ELISA-based quantification of intracellular cGMP in primary cultures from
P12 mice. Cultures were treated with BNP (100 or 500 ng/ml for 5, 10 or 30 min) and/or anantin (100 and 500 nM, 30 min), or
treated with vehicle (indicated as 0). Note large rise in cGMP that declines at 60 min; anantin alone (500 nM) decreases basal
cGMP. Data were normalized to the total protein content in each sample and are presented as mean value ± SEM (n=3). *p≤0.05. B
(top), example of western blot of Akt phosphorylation induced by BNP (500 ng/ml) applied alone or together with anantin (100 and
500 nM) for various times as indicated. Bottom histograms quantify these data from at least 3 experiments, demonstrating early and
transient increment in P-Akt expression.
doi: 10.1371/journal.pone.0081138.g003
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nM anantin, yet insensitive to 100 nM antagonist concentration.
It was of interest that the increment in Akt phosphorylation was
not sustained as it declined at 30 min and disappeared 24 h
later (Figure 3 B).
These experiments, thus, demonstrated that functional NPR-
A receptors were found in TG cultures despite the poor
expression of BNP. We wondered if activation of these
receptors could be translated into changes in the activity of
ligand-gated neuronal channels considered to be important
transducers of nociceptive signals. For this purpose, we
studied how BNP application could affect electrophysiological
responses mediated by P2X3 or TRPV1 channels.
Effect of BNP on P2X3 and TRPV1 receptors
Patch clamp experiments were run to test whether short or
long term application of 100 ng/ml BNP could change
responses evoked by α,β-meATP (10 µM) or capsaicin (1 µM)
to activate P2X3 or TRPV1 receptors, respectively [18]. As a
reference, we also tested the inward, Cl- mediated currents
generated by GABA (10 µM) via activation of GABAA receptors
[44,45]. Only one concentration of BNP (100 ng/ml) was used
for electrophysiological experiments, since we had shown it to
be sufficient to activate NPR-A-mediated pathways and to
increase significantly cGMP levels (Figure 3 A); the same BNP
concentration was also used in previous studies, showing its
effectiveness on DRG neurons [25].
Figure 4 A shows that continuous superfusion with BNP (100
ng/ml for 10 min) did not change sample responses to these
three ligands. Furthermore, BNP did not change cell input
resistance (528±50 MΩ in control versus 552±57 MΩ in the
presence of BNP; n=28) or baseline current (84±15 versus
79±11 pA before and after BNP, respectively; n= 28).
Preincubating cultures for 2 h with 100 ng/ml BNP also failed to
alter the responses mediated by P2X3, GABAA or TRPV1
receptors (Figure 4 B). Nonetheless, 24 h application of 100
ng/ml BNP significantly and selectively depressed the currents
evoked by 1 µM capsaicin (Figure 5 A, see arrows). This effect
was also observed for other capsaicin concentrations (0.1 µM,
0.5 and 5 µM; see Figure 5 B) as the dose/response plot was
shifted downwards after chronic application of BNP.
We next explored whether this slow action by BNP could be
attributed to the consequence of NPR-A receptor activation
followed by a rather slow series of events culminating in
TRPV1 channel modulation. Should this hypothesis be correct,
the effects of BNP ought to be suppressed by the selective
antagonist of NPR-A anantin [32,41,42]. Thus, we first
validated the use of anantin, that, when applied alone at 500
nM (to ensure a complete blockage of NPR-A; Figure 3 A, B),
did not change control responses to capsaicin α,β-meATP.
Figure S1 B shows that preapplication of anantin (500 nM; 10
min) failed to change P2X3 receptor responses. Likewise,
responses evoked by capsaicin (1 µM) were 11.9±4.3 pA/pF
(n=6), a value not significantly different from the one observed
after anantin (9.5±5.1 pA/pF, n=4), suggesting no direct
channel modulation by anantin.
Figure 5 C shows that the inhibitory effect on TRPV1
receptors seen after 24 h application of BNP was fully
prevented by concomitant administration of 500 nM anantin
(that per se had no effect on capsaicin-induced responses
even when chronically applied). No significant change in P2X3
receptor-mediated currents was present after 24 h BNP
application (Figure 5 D). It was, however, interesting to observe
that anantin (500 nM; 24 h) per se enhanced responses to α,β-
meATP (10 µM), that were almost twice (196 %) their controls
(Figure 5 E). This effect was detected at various agonist
concentrations as the α,β-meATP dose-response curve was
shifted leftwards without significant change in the maximum
response amplitude (Figure 5 F). When anantin plus BNP were
continuously co-applied for 24 h, the potentiation of the P2X3
receptor currents persisted (Figure 5 E). Figure 5 G shows that
24 h application of BNP (100 ng/ml) or anantin (500 nM) did not
change the expression level of either TRPV1 or P2X3
receptors. Finally, we did not find any change in GABA-
mediated currents after applying BNP, or anantin, or their
combination (Figure 5 H, I).
Although short-term BNP and/or anantin application was
sufficient to produce fast changes in cGMP levels or Akt
phosphorylation, modulation of TRPV1 or P2X3 currents
appeared only after 24 h of BNP and/or anantin exposure.
Thus, we wondered if even a short BNP or anantin treatment
could trigger a very delayed receptor modulation. For this, we
applied BNP (100 ng/ml) or anantin (500 nM) for 1 h only and,
after overnight wash, patch-clamping was performed. With this
protocol, the effects of BNP and anantin on TRPV1 or P2X3
currents were no longer observed (Figure S2).
Discussion
The principal result of our study is the novel demonstration of
widespread expression of functional NPR-A receptors in mouse
TG neurons (against a modest expression of BNP), and their
ability to modulate TRPV1 and P2X3 receptor activity with a
characteristically delayed timecourse. Thus, these data outline
a new downregulation by the BNP system of the two major
nociceptive signal transducers [1-5] of TG sensory neurons.
The influence of the natriuretic peptide system on
nociception has only recently come to light. A study by Zhang
and colleagues [25] has shown, in control conditions, high
levels of BNP and low expression of NPR-A in the rat DRG. In
our experiments with in vivo and in vitro mouse TG tissue, we
found a different phenomenon, namely low BNP presence and
almost universal neuronal expression of NPR-A, that, with
biotinylation experiments, was demonstrated to be localized at
membrane level.
The cellular distribution of BNP and NPR-A was well
preserved in vitro, indicating that TG cultures could represent a
suitable model to explore the BNP mode of action. It is
noteworthy that, while the NPR-A expression was exclusively
neuronal and included virtually all somatic sizes, the
expression of BNP could be detected in a few non-neuronal
cells, alluding to a role of this peptide in the growing family of
neuropeptides involved in neuron/non-neuronal cell crosstalk at
ganglion level [19,20]. The scant occurrence of BNP
immunopositive cells could not be attributed to an artifact of the
histological procedure as lack of signal was noted even with
freshly frozen sections of the trigeminal ganglion. Some
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neuropeptides, like vasoactive intestinal polypeptide, galanin
and NPY, are normally expressed at low or undetectable levels
in sensory neurons and a specific stimulus is required for these
peptides to be upregulated [46]. In keeping with this view, the
concentration of BNP in ganglia in situ or in primary cultures
was low, yet clearly detectable even in the extracellular
Figure 4.  Ten min or 2 h BNP application does not affect capsaicin-, α,β-meATP- or GABA-mediated responses.  A,
Representative traces of currents induced by pulse application of α,β-meATP (10 µM, 2 s), capsaicin (1 µM, 3 s), or GABA (10 µM,
2 s) to TG neurons in control conditions or after application of BNP (100 ng/ml, 10 min) to the same cells. Histograms show average
current density values of P2X3, TRPV1 or GABA-mediated responses (n=12, 12, 11, respectively). B, Histograms show average
current density values of P2X3, TRPV1 or GABA-mediated responses in control conditions (n=52, 73, 123, respectively) or after 2 h
application of 100 ng/ml BNP (n=42, 53, 119).
doi: 10.1371/journal.pone.0081138.g004
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Figure 5.  Changes in current responses produced by capsaicin, α,β-meATP or GABA following 24 h BNP application.  A,
Histograms show average current density values of TRPV1-mediated responses induced by 1 µM capsaicin in TG neurons under
control conditions or after 24 h application of BNP (100 ng/ml); n=151 and 109 for control and after application of BNP, respectively;
*p= 0.00014. Inset shows an example of superimposed currents of one neuron in control and after BNP treatment. B, Dose-
response curves for capsaicin mediated currents in control and after 24 h BNP treatment (100 ng/ml); *p<0.035; n≥ 15 for each
agonist concentration. C, Histograms summarize average current density values of the responses to 1 µM capsaicin in control
conditions, after 24 h application of 500 nM anantin, or anantin plus 100 ng/ml BNP (n=53, 50, 43, respectively). D, E, Histograms
show average current density values of P2X3-mediated currents in control conditions and after 24 h application of BNP (100 ng/ml);
n=74 and 76, respectively. Anantin alone significantly increases these values compared to control, an effect not reversed by co-
application with BNP (n=69, 63, 64, respectively); *p<0.0001. F, Dose-response curves for α,β-meATP mediated currents in control
and after 24 h exposure to 500 nM anantin ; *p<0.035; n≥14 for each agonist concentration. G, Western blot analysis of TRPV1 or
P2X3 receptor expression 24 h after applying BNP (100 ng/ml) or anantin (500 nM); data are from 3 experiments. H, I, Histograms
show no change in GABA-mediated responses after 24 h application of BNP (100 ng/ml; n=25 and 27, respectively). Likewise, there
is no change after application of anantin alone, or with BNP (n=73, 73, or 86, respectively).
doi: 10.1371/journal.pone.0081138.g005
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medium of the primary cultures where it is expected to be
concentrated by the lack of continuous blood circulation. It
seems feasible that certain stimuli (yet to be identified) might
raise BNP levels to become more functionally relevant for
modulation of ganglion neurons.
The application of exogenous BNP rapidly evoked a large
increase in cGMP level, a canonical effector of BNP [28], that
peaked at about 30 min and then declined. This phenomenon
was fully inhibited by the selective NPR-A antagonist anantin.
Downstream of NPR-A activation and cGMP production is
phosphorylation of Akt [40], an intracellular kinase targeting
multiple pathways in cell signalling [47]. In accordance with this
notion, BNP significantly enhanced Akt phosphorylation, an
effect of transient nature (like the cGMP increment) as it was
lost after 1 h.
The relatively quick onset of biochemical effects of BNP and
the widespread neuronal expression of its receptor might have
suggested an early change in the activity of the receptors like
TRPV1 and P2X3 on nociceptors. Nevertheless, we found no
significant change in neuronal currents induced by capsaicin,
α,β-meATP, or GABA when BNP was applied for up to 2 h.
Likewise, in the presence of BNP, there was no change in
neuronal input resistance or baseline current, implying that the
peptide produced neither a rapid alteration in background
conductances regulating neuronal excitability nor a direct
change in membrane permeability. We suggest that the
relatively fast onset of biochemical effects evoked by BNP
against lack of early electrophysiological action indicates a
complex intracellular signalling system that triggers
comparatively slow modifications in neuronal activity. This
phenomenon would be compatible with a role of BNP in
controlling chronic rather than acute pain. It is worth mentioning
that, in rat DRG neurons, BNP rapidly enhances the activation
of voltage-dependent potassium channels only when
extracellular glutamate is persistently increased [25].
Despite the waning of BNP-induced rise of cGMP level and
Akt phosphorylation following prolonged exposure, 24 h
application of the peptide significantly depressed the currents
evoked by capsaicin and shifted downwards the dose/response
plot, suggesting systematic inhibition of TRPV1 receptor
activity. This effect was prevented by anantin that per se did
not change TRPV1 receptor responses. The same BNP
application protocol had no effect on P2X3 receptor responses
(or those mediated by GABA). Nonetheless, chronic anantin
administration per se significantly augmented currents induced
by various concentrations of α,β-meATP, with a lateral shift of
the dose/response plot that did not change its maximum. This
finding suggested that there was ambient release of BNP
sufficient to inhibit P2X3 receptors, a notion fully compatible
with the ELISA assay of this peptide in culture. This suggestion
is also supported by the decreased cGMP level observed in the
presence of anantin alone. When the NPR-A receptors were
blocked by anantin (500 nM) with consequent facilitation of
P2X3 receptor activity, co-applied BNP could not reverse this
phenomenon. It is noteworthy that short application of anantin
(or BNP) per se did not rapidly alter currents evoked by
capsaicin or α,β-meATP. Furthermore, testing neurons 24 h
after a short application of anantin or BNP failed to detect any
receptor modulation. Overall, these findings are consistent with
the view that modulation of the responses to capsaicin or α,β-
meATP was a rather delayed consequence of NPR-A receptor
occupation rather than a direct interaction of anantin with
TRPV1 or P2X3 channels. The observed phenomenon that a
NPR-A blocker could slowly enhance P2X3 receptor activity is
reminiscent of a well-known process formerly described for
TRPV1 receptors that are constitutively inhibited by
phospholipids such as PIP2: when PIP2 hydrolysis is
suppressed, TRPV1 function is slowly augmented [48].
Although the present report did not explore the molecular
mechanisms linking NPR-A activation to TRPV1 and P2X3
receptor changes, a few clues might emerge by comparing the
present data with former studies of sensory ganglion
modulators. While further investigations are necessary to
identify the precise reason whereby the modulation by BNP of
TRPV1 and P2X3 receptors occurred so late, it is worth noting
that, on trigeminal ganglia, modulation of P2X3 receptors by
other peptides such as CGRP [20,39], bradykinin [48,49], or
NGF deprivation [50] is typically slow in onset and persistent as
multiple intracellular cascades are believed to be involved.
Likewise, modulation of TRPV1 receptor function by growth
factors (NGF, GDNF; [51]) or the cytokine TNF-α is also slow
[52]. Since after 24 h exposure to BNP or anantin there was no
change in the expression of TRPV1 or P2X3 protein in ganglion
cell lysates, a possible target for BNP modulation is
hypothesised to be the turnover process of these receptors
[53,54] which might have shifted the balance between receptor
compartments at membrane and cytosol level with consequent
reduction in membrane current responses.
It is also emphasized that the strong expression of NPR-A by
TG neurons (despite the poor presence of BNP) would make
the TG particularly sensitive to circulating BNP released by a
variety of peripheral tissues under physiological and
pathological conditions [28]. Hence, the NPR-A system might
represent a slow regulator of sensory excitability.
While in vivo experiments using trigeminal pain conditions
will be necessary to establish the functional outcome of NPR-A
activity, our data suggest that BNP/NPR-A signaling could have
antinociceptive functions. Conversely, NPR-C receptors are
present in DRG (and colocalized with TRPV1 channels) and
are activated by CNP to enhance thermal hyperalgesia in a
protein G βγ- and PKC-dependent fashion [24]. These results
indicate the coexistence of functional NPRs in DRG that exhibit
contrasting effects in pain transduction.
Trigeminal sensory neurons constitute the peripheral
component of the so-called trigeminovascular system, an
important pain complex thought to play a central role in primary
headache syndromes, such as migraine [55,56]. Several
neuropeptides contribute to the development of migraine pain:
for example, CGRP increases the expression and the
membrane targeting of P2X3 receptors [19,20,39], and
bradykinin upregulates TRPV1 channels [57]. These mediators
have the common ability to alter both neuronal and vascular
function, a property shared by natriuretic peptides, which
modulate nociceptive transmission at DRG level [24,25]. Since
migraine patients display higher proBNP serum levels
compared to healthy subjects [38], these data together with the
BNP Modulates TRPV1 and P2X3 Receptors
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e81138
present findings indicate the desirability for future studies to
address the potential involvement of the natriuretic peptide
system in migraine pathophysiology.
Methods
All experiments involving the use of mice and the procedures
followed therein were approved by the Scuola Internazionale
Superiore di Studi Avanzati (SISSA) ethics committee and are
in accordance with the European Union guidelines. Animals
were maintained in accordance with the guidelines of the Italian
Animal Welfare Act.
Preparations of mouse trigeminal ganglia and
immunostaining
Primary cultures of P12 mouse trigeminal ganglia were
prepared as described previously [18,39] and used 24 h after
plating.
For immunohistochemistry, mice were deeply anesthetized
with intraperitoneal injection of urethane (0.3 ml of 1 g/ml;
Sigma, Milan, Italy) and perfused transcardially with phosphate
buffer solution followed by 4% paraformaldehyde. Trigeminal
ganglia were removed, postfixed for 1 h at room temperature
and cryoprotected overnight in 30% sucrose at 4°C. Each
immunohistochemistry experiment was performed on an
average of 5 cryostat-cut serial longitudinal slices (14 µm-thick)
sampled every ~70 µm, and thus covering the entire ganglion.
Samples were incubated in a blocking solution containing 5%
bovine serum albumin, 1% fetal bovine serum and 0.1% Triton
X-100 in phosphate saline buffer for 2 h at room temperature,
and immunostained with primary (for 16 h at 4°C) and
secondary antibodies (2 h at room temperature). Antibodies
against NPR-A (1:1000; Abcam, Cambridge, UK), BNP (1:100;
Phoenix Pharmaceuticals, Burlingame, CA, USA) and β-tubulin
III (1:1000; Sigma) were used. The specificity of the NPR-A
antibody used in this study has been previously validated [25].
Secondary antibodies conjugated with Alexa Fluor-488 or
Alexa Fluor-594 were purchased from Invitrogen (1:500; Milan,
Italy). Nuclei were counterstained with DAPI (Sigma). The
scant immunostaining for BNP led us to check whether this
phenomenon could be attributed to a fixation artifact. Thus, we
cut, with a cryostat, freshly frozen ganglia (14 µm sections) and
processed them for BNP immunoreactivity using the blocking
solution indicated above. Even in this case, BNP signals were
absent or very rare. Double immunofluorescence experiments
were performed using Zenon Technology: the anti-NPR-A
antibody was labeled with Zenon Alexa-594 rabbit IgG labeling
reagent as per manufacturers’ instructions (Invitrogen). Images
from whole ganglion sections were visualized with Leica
confocal microscope (Leica TCS SP2, Wetzlar, Germany) or a
Zeiss Axioskop fluorescence microscope (Zurich, Switzerland).
Similar procedures were used for fluorescence immunostaining
of cultured mouse TG neurons [18,58]. MetaMorph software
(Molecular Devices, Downingtown, PA, USA) was employed for
data analysis.
Western blot
Western blot analysis was performed according to the
methods previously reported [58,59]. Cells were lysed in buffer
solution (2% n-octyl-beta-D-glucopyranoside, contaning 1%
Nonidet P-40, 10 mM Tris pH 7.5, 150 mM NaCl plus protease
inhibitors mixture; Complete, Roche Applied Science, Basel,
Switzerland) and immunoblotted with rabbit anti-NPR-A
(1:1000, Abcam), anti-β-tubulin III (1:2000; Sigma) or anti-β-
actin (1:3000, Sigma) antibodies. For Akt phosphorylation
assays, cells were lysed in phosphate buffer solution
containing 0.1% SDS, 1% sodium deoxycholate, and 1% triton
X-100, and immunoblotted with anti-phospho-Akt Ser473
(1:1000; Cell Signaling, Danvers, MA, USA), anti-Akt (1:1000;
Cell Signaling) or anti-β-actin-HRP (1:3000; Sigma). Signals
were detected with the enhanced chemiluminescence light
system ECL (Amersham Biosciences, Piscataway, NJ, USA)
and recorded by the digital imaging system Alliance 4.7
(UVITEC, Cambridge, UK). Quantification of the optical density
of the bands was performed with ImageJ software plug-in
(Rasband, W.S., ImageJ, US National Institutes of Health,
Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997-2012).
Biotinylation of surface expressed receptors
For biotinylation experiments, cells were incubated with 1
mg/ml EZ-Sulfo-NHS-LC-biotin (Pierce, Rockford, IL, USA) as
previously described [39,60]. Pull-down of biotinylated proteins
was obtained with Streptavidin agarose resin (Pierce) for 2 h at
4°C according to the manufacturer’s instructions. Samples
were processed for Western immunoblotting using antibodies
against the NPR-A receptor (1:1000). Biotinylation experiments
resulted to be free of intracellular protein contaminants (as
shown by lack of signal for β-actin). Positive control for
biotinylation assay was obtained by checking the surface
expression of the transferrin receptor detected with an antibody
purchased from Santa Cruz Biotechnology (1:1000,
Heidelberg, Germany). For control of correct gel loading, the
expression of β-actin in the intracellular fraction was checked.
RNA isolation, reverse transcription and RT-PCR
Total RNA was extracted from mouse intact TG tissue
samples using Trizol reagent (Invitrogen) according to the
manufacturer’s instruction. All RNA samples were subjected to
DNase I treatment (Ambion, Monza, Italy). A total of 1 μg of
RNA was subjected to retrotranscription using iScript cDNA
synthesis kit (BioRad, Hercules, CA, USA) and RT–PCR was
carried out using SYBR green fluorescence dye (2× iQ5 SYBR
Green supermix, BioRad) as described previously [61]. Specific
primer sets for NPR-A [62], BNP [63], GAPDH [64] and β-actin
[65] were previously described.
Assay for intracellular cGMP production in TG cultures
Quantification of BNP-induced intracellular cGMP production
in mouse TG cultures was performed using a direct ELISA kit
(MBL International Corporation, Woburn, MA, USA) following
the instructions of the manufacturer. Briefly, cultures were
lysed in 0.1 M HCl and subjected to determination of
intracellular cGMP concentration. The protein concentrations in
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cell lysates were determined by the BCA method (Sigma).
Intracellular cGMP concentrations were expressed as pmol of
cGMP per µg of protein. Three independent experimental
replicates were generated from three different batches of
mouse TG cultures.
Serum sampling and ELISA assay for BNP
Blood was sampled from the retro-orbital sinus of mice,
immediately transferred to chilled microtubes on ice for 30 min
and centrifuged at 10,000 g at 4°C for 10 min. Culture medium
was collected from TG cultures 24 h after plating and
centrifuged at 10,000 g at 4°C for 10 min. From the same
cultures, cells were lysed in 0.1 M HCl and centrifuged at
10,000 g at 4°C for 10 min. Protein concentrations in cell
lysates were determined by the BCA method (Sigma). Tissue
and medium samples were immediately used for ELISA assay
to determine BNP concentrations following the instructions of
the manufacturer (Abnova, Hidelberg, Germany). All samples
were run in triplicate and values averaged.
Electrophysiology and data analysis
Electrophysiology experiments were performed according to
the methods previously reported [17,18]. Briefly, after 24 h in
culture, TG neurons were superfused continuously (3 mL/min)
with physiological solution containing (in mM): 152 NaCl, 5 KCl,
1 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES (pH adjusted to
7.4 with NaOH). Cells were patch-clamped in the whole-cell
configuration using pipettes with a resistance of 3-4 Mʊ when
filled with the following solution (in mM): 140 KCl, 0.5 CaCl2, 2
MgCl2, 2 Mg2ATP3, 2 GTP, 10 HEPES, and 10 EGTA (pH
adjusted to 7.2 with KOH). Recordings were performed from
small and medium size neurons that mostly express TRPV1
and/or P2X3 receptors [17,18]. Cells were held at -65 mV;
membrane currents were filtered at 1 kHz and acquired by
means of a DigiData 1200 interface and pClamp 8.2 software
(Molecular Devices, Sunnyvale, CA, USA). To obtain stable
and reproducible P2X3 receptor currents, its synthetic agonist
α,β-methylene-adenosine-5’-triphosphate (α,β-meATP; Sigma)
at the concentration of 10 µM that elicits near-maximal
responses [58,64,66] was applied (for 2 s) using a fast
superfusion system (Rapid Solution Changer RSC-200;
BioLogic Science Instruments, Claix, France). α,β-meATP at 1,
3, 5, 30 and 100 µM concentrations was additionally studied to
obtain dose-response curves in control and experimental
conditions. In line with previous reports [17,58], capsaicin
(Sigma) was applied at the concentration of 1 µM (3 s) to evoke
reproducible inward currents. Additionally concentrations 0.1,
0.5, 5 and 10 µM were included to obtain capsaicin dose-
response curves under control conditions and after the
treatment. GABA (10 µM) was applied with 2 s pulses [45].
Peak current amplitudes were divided by the cell slow
capacitance to express responses as current density values.
For patch clamp experiments, various protocols were used to
test the effect of BNP on these ligand-gated channels. In a
series of experiments, BNP was continuously superfused
(starting 10 min prior to the agonist pulses) at 100 ng/ml
concentration while agonist responses were repeatedly tested.
In other experiments, TG cultures were incubated with BNP
solution (100 ng/ml) for 2 or 24 h; after washing out the
peptide, cells were immediately patch-clamped and tested for
their responsiveness to the agonists. In the third type of the
protocol BNP was applied for 1 h and, after wash out, cells
were incubated for 23 h in the usual medium before the
experiment. A similar approach was employed for the NPR-A
antagonist anantin (500 nM) applied either alone or together
with BNP.
Chemicals and reagents
Purified recombinant mouse BNP was purchased from
Phoenix Pharmaceuticals; the specific NPR-A antagonist
anantin was from US Biologicals (Salem, MA, USA). BNP and
anantin were dissolved in distilled water as the datasheet
suggested. BNP was applied at the dose of 100 ng/ml, as
previously performed for sensory ganglia [25], and 500 ng/ml.
Anantin was applied at the dose of 100 nM and 500 nM as
previously reported [67].
To inhibit NPR-A receptor activity, we used anantin since, to
the best of our knowledge, it is the only specific and selective
NPR-A antagonist [41–43], devoid of agonistic activities [68],
unlike commercially-available antagonists which are not
selective on NPR subtypes [69–72], and which may also
possess agonistic activities [73].
Statistical analysis
Data were collected from at least three independent
experiments, and are expressed as mean ± standard error of
the mean (SEM), where n indicates the number of independent
experiments or the number of investigated cells, as indicated in
figure legends. Statistical analysis was performed using the
Student’s t-test or the Mann-Whitney rank sum test, after the
software-directed choice of parametric or non-parametric data,
respectively (Sigma Plot and Systat Software Inc., San Jose,
CA, USA). A p value of ≤ 0.05 was accepted as indicative of a
statistically significant difference.
Supporting Information
Figure S1.  Co-localization of NPR-A with TRPV1 and P2X3
receptors, and lack of acute NPR-A block on P2X3 receptor
responses. A, Example of confocal microscopy images
showing the colocalization of immunostaining for NPR-A (red)
and TRPV1 or P2X3 (green). Cell nuclei are visualized with
DAPI staining (blue). Scale bar, 30 µm. B, Representative
traces of currents induced by pulse application of α,β-meATP
(10 µM, 2 s) to TG neurons in control conditions or after
application of anantin (500 nM, 10 min) to the same cells.
Histograms show average current density values of P2X3-
mediated currents (n=18).
(TIF)
Figure S2.  1 h BNP or anantin application has no effect on
capsaicin-, α,β-meATP- or GABA-mediated responses
recorded 23 h later. Histograms show average current density
values of P2X3, TRPV1 or GABA-mediated responses in
control conditions (n=40, 58, 82, respectively) or 23 h after 1 h
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